Multiple Sclerosis Drugs - EMEA

EMEA

Revenue in the Multiple Sclerosis Drugs market is projected to reach US$4.60bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 1.02%, resulting in a market volume of US$4.79bn by 2028.
In global comparison, most revenue will be generated in the United States (US$11,770.00m in 2024).

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

Due to generic competition, growth in the Multiple Sclerosis Drugs market is only moderate in the time span considered. The market has been affected negatively by the COVID-19 pandemic because of limited access to healthcare professionals, leading in particular to fewer new patients. As multiple sclerosis treatments are of a long-term nature, revenues are expected to recover only marginally, resulting in a slightly lower forecast level than previously projected.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.